Profile Information
- Affiliation
- School of Medicine, Fujita Health UniversityCollege of Pharmacy, Kinjo Gakuin UniversityNational Institute of Infectious DiseasesNagoya University
- Degree
- 医学博士(Mar, 1989, 名古屋大学)
- Researcher number
- 10212622
- J-GLOBAL ID
- 201101032201306103
- Researcher ID
- P-5997-2015
- researchmap Member ID
- 6000030043
In the 1980s, I found that the chromosomal β‐lactamase of Klebsiella pneumoniae
LEN‐1 showed a very high similarity to the R‐plasmid‐mediated penicillinase
TEM‐1 on the amino acid sequence level, and this strongly suggested the origination
of TEM‐1 from the chromosomal penicillinases of K. pneumoniae or related
bacteria. Moreover, the chromosomal K1 β‐lactamase (KOXY) of Klebsiella oxytoca
was found to belong to the class A β‐lactamases that include LEN‐1 and TEM‐1,
although KOXY can hydrolyze cefoperazone (CPZ) like the chromosomal AmpC type
cephalosporinases of various Enterobacteriaceae that can hydrolyze several
cephalosporins including CPZ. Furthermore, my collaborators and I found plural
novel serine‐type β‐lactamases, such as MOX‐1, SHV‐24, TEM‐91, CTX‐M‐64,
CMY‐9, CMY‐19, GES‐3, GES‐4, and TLA‐3, mediated by plasmids. Besides these
serine‐type β‐lactamases, we also first identified exogenously acquired metallo‐
β‐lactamases (MBLs), IMP‐1 and SMB‐1, in imipenem‐resistant Serratia marcescens,
and the IMP‐1‐producing S. marcescens TN9106 became the index case for
carbapenemase‐producing Enterobacteriaceae. I developed the sodium mercaptoacetic
acid (SMA)‐disk test for the simple identification of MBL‐producing
bacteria. We were also the first to identify a variety of plasmid‐mediated 16S
ribosomal RNA methyltransferases, RmtA, RmtB, RmtC, and NpmA, from various
Gram‐negative bacteria that showed very high levels of resistance to a wide
range of aminoglycosides. Furthermore, we first found plasmid‐mediated quinolone
efflux pump (QepA) and fosfomycin‐inactivating enzymes (FosA3 and FosK).
We also first characterized penicillin reduced susceptible Streptococcus agalactiae (PRGBS),
macrolide‐resistant Mycoplasma pneumoniae, as well as Campylobacter jejuni, and
Helicobacter pylori, together with carbapenem‐resistant Haemophilus influenzae.
Research Interests
2Research Areas
3Major Research History
30-
Apr, 2020 - Present
-
Apr, 2020 - Present
-
Apr, 2020 - Mar, 2024
Education
3-
Apr, 1985 - Mar, 1989
-
Nov, 1984 - Mar, 1985
-
Apr, 1975 - Sep, 1983
Committee Memberships
29-
Oct, 2023 - Present
-
Mar, 2022 - Present
-
Jul, 2012 - Present
-
Apr, 2011 - Present
-
Apr, 2005 - Present
Awards
3Papers
301-
Biological and Pharmaceutical Bulletin, 49(4) 691-700, Apr 14, 2026
-
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 31(12) 102846-102846, Dec, 2025Several studies have reported clinical isolates of Streptococcus mitis, Streptococcus oralis, and their related species (S. mitis/oralis group) with reduced carbapenem susceptibility. However, to date, no simple and accurate methods of detecting S. mitis/oralis group isolates with reduced carbapenem susceptibility have been reported. The meropenem ETEST misinterpreted 3 of 25 (12 %) meropenem-non-susceptible S. mitis/oralis group isolates as susceptible to meropenem. Therefore, we screened 38 disks containing 38 different β-lactams to detect S. mitis/oralis group strains with reduced carbapenem susceptibility using the disk-diffusion method. Additionally, using the agar dilution method to determine susceptibility, we identified the optimal antibiotic concentrations in agar medium to enable selective culture of meropenem-non-susceptible S. mitis/oralis group by culturing 25 meropenem-non-susceptible (meropenem minimum inhibitory concentration [MIC] >0.5 μg/mL) and 24 meropenem-susceptible (meropenem MIC ≤0.5 μg/mL) S. mitis/oralis group isolates on agar containing different concentrations of six β-lactams. Meropenem-susceptible and non-susceptible S. mitis/oralis group isolates were successfully differentiated using oxacillin- and cefoxitin-containing disks. Moreover, cefdinir-, flomoxef-, meropenem-, and doripenem-containing disks showed clear differences in the growth inhibitory zone diameter between the meropenem-susceptible and meropenem-non-susceptible S. mitis/oralis group isolates. Media containing 2 μg/mL oxacillin, 4-16 μg/mL cefoxitin, 2 μg/mL cefdinir, 2-4 μg/mL flomoxef, 0.06-0.25 μg/mL meropenem, and 0.06-0.12 μg/mL doripenem allowed selective culture of meropenem-non-susceptible S. mitis/oralis group strains. The disk-diffusion method using six β-lactam-containing disks and selective culture agar medium are the first-reported simple and accurate methods of detecting meropenem-non-susceptible S. mitis/oralis group suitable for use in clinical microbiology laboratories.
-
Journal of Microbiological Methods, 237 107235-107235, Oct, 2025 Peer-reviewed
-
Journal of Antibiotics(Tokyo), Jul 9, 2025 Peer-reviewed
-
PloS one, 20(8) e0329635, 2025INTRODUCTION: Antimicrobial resistance in Pseudomonas aeruginosa is one of the global health concerns. Like many countries, Japan monitors multidrug-resistant P. aeruginosa (MDRP) infections through a national sentinel surveillance system, which has shown a recent decline in MDRP reports. We evaluated this surveillance system to verify the validity of this trend and explore future directions. METHODS: We conducted a cross-sectional mixed-method study based mainly on the guidelines published by the United States Centers for Disease Control and Prevention in 2001. As a quantitative method, we analyzed characteristics of reports on MDRP infections from designated sentinel sites (DSSs) between 2013-2022. A questionnaire was sent to identifiable DSSs (target DSSs) requesting data on accurate numbers of MDRP infections between 2018-2022 to assess attributes such as geographical representativeness. Additionally, we conducted as a qualitative method face-to-face, semi-structured key informant interviews with surveillance system stakeholders to assess its usefulness and challenges. RESULTS: From 2013 to 2022, 1,666 cases of MDRP infections were reported by 463 target DSSs, which were scattered across the county. We obtained valid responses to the questionnaire survey from 231 target DSSs (49.9%). From 2018 to 2022, these sites reported 277 cases as MDRP infections, while 184 cases were accurate cases of MDRP infection, with both numbers declining over time. False reporting and underreporting of MDRP infections were common, resulting in a positive predictive value of 0.45 and a sensitivity of 0.65 for the reports of MDRP infections to the surveillance system. The interviews highlighted the difficulties in timely detection, accurate reporting, and international data comparison. CONCLUSION: Our evaluation indicated that the current sentinel surveillance system for MDRP infections partially captured the true decreasing trend in Japan. However, as the epidemiology of drug-resistant P. aeruginosa is changing, national policy and surveillance strategies would need to address changing public health needs.
Misc.
1124-
日本血液学会・日本臨床血液学会総会プログラム・抄録集, 66回・46回 761-761, Sep, 2004
-
環境感染, 19(3) 389-394, Aug, 2004院内感染は不全臓器数や死亡の増加および医療費の増加をもたらすことが知られている.院内感染対策を推進するうえで,基礎資料として,院内感染による医療負担の現状を明らかにすることが求められている.そこで,厚生労働省院内感染対策サーベイランス事業のICU部門の研究班のデータベースを用いて,ICU内院内感染による医療負担を死亡の増加と入院期間の延長という2つの観点から評価した.ICU内院内感染による死亡の増加と入院期間の延長を認めた.このようなICU内院内感染の影響はとくにAPACHEスコアの低い軽症例において有意であったことから,ICUにおける院内感染対策はAPACHEスコアの高い重症例よりもAPACHEスコアの低い軽症例においてより重要になると考えられた
-
環境感染, 19(3) 395-400, Aug, 2004厚生労働省院内感染対策サーベイランス事業のICU部門の研究班のデータベースを用いて,術後患者の割合によるICU施設属性の違いをしらべ,ICU施設属性とICU内院内感染の関係を明らかにした.術後患者の割合によるICU施設属性とICU内院内感染の関連を認めた.ICUサーベイランスデータを評価するにあたり,ICU施設属性を考慮する必要があると考えられた
-
山形市立病院済生館医学雑誌, 29(1) 83-89, Aug, 20042000年10月から2003年3月までに自院の検査室で分離された1967株の腸内細菌について基質特異性拡張型βラクタマーゼ産生菌のスクリーニングを試みた.遺伝子解析の結果,院内感染が示唆される2株が認められた
-
Helicobacter Research, 8(4) 321-325, Aug, 2004 Last authorHelicobacter pylori(H.pylori)より,これまでに知られている病原因子とはまったく異なるアポトーシス誘導蛋白を精製,同定した.この蛋白はγ-glutamyl transpeptidase(GGT)活性をもつものであった.GGTを欠損させたisogenic mutant株は,親株にくらべてアポトーシス誘導活性が有意に低かった.著者らが見出したGGT蛋白はH.pyloriのアポトーシス誘導活性のなかで最も重要な役割を果たすもののひとつであると考えられ,このことは今までに知られていない全く新しい知見である
-
薬剤耐性菌シンポジウム講演記録, 33回 43-44, Jul, 2004
-
日本臨床微生物学雑誌, 14(2) 104-110, Jul, 200473歳男.糖尿病で通院加療である.基礎疾患である糖尿病と慢性腎不全治療のため,入院した.腎機能障害増悪のため入院直後より腎透析を開始した.腎透析時,頻回にバンコマイシン(VCM)を投与されていた.左下肢壊死部褥創からVCM,テイコプラニン(TEIC)共に高度耐性を示すEnterococcusを分離し,生化学性状および16S rRNAの解析による遺伝子学的同定により,E.raffinosusを確認した.またVan型を確認するために行ったPCR解析では,既存のプライマーにより増幅がかからなかったため,新たに細菌のD-Ala-D-Ala ligaseを増幅可能なPCRプライマーを設計した.PCR増幅されたDNA断片をシークエンスしたところvanD4と高い相同性を確認した
-
日本細菌学雑誌, 59(2) 415-424, May, 2004 Last authorHelicobacter pylori(H.pylori)は,宿主細胞の様々な細胞内シグナル経路を活性化する作用を持つことが明らかになっている.この細胞内シグナル経路への種々の作用が,この菌の長期持続感染の成立と,それに続く様々な病態の発生にあたって重要な要因になっていると考えられる.H.pyloriの病原性は,菌側および宿主側の複数の因子が長期的に相互に作用した複雑な系によるものと考えられ,病態の全体像は未だ不明な部分が多い
-
日本薬学会年会要旨集, 124年会(3) 21-21, Mar, 2004
-
5(2) 23-29, 2004 Peer-reviewedInvitedLast author
-
Yakugaku Zasshi, 124 43-43, 2004
-
新型の薬剤耐性菌のレファレンス並びに耐性機構の解析及び迅速・簡便検出法に関する研究 平成15年度 研究報告書, 156, 2004
-
新型の薬剤耐性菌のレファレンス並びに耐性機構の解析及び迅速・簡便検出法に関する研究 平成15年度 研究報告書, 136, 2004
-
日本臨床微生物学雑誌, 13(4) 114-114, Dec, 2003
Books and Other Publications
27Presentations
108Teaching Experience
1-
1989 - Present医学細菌学、病原細菌学、薬剤耐性菌等 (名古屋大学 [医、保健、工]、群馬大学 [医]、千葉大学 [薬]、東京薬科大学 [薬]、愛知学院大学 [歯・薬]、岐阜薬科大学 [薬]、愛知医科大学[医]、 他)
Professional Memberships
6Research Projects
32-
創薬支援推進事業・創薬総合支援事業, 日本医療研究開発機構(AMED), Apr, 2022 - Mar, 2025
-
創薬支援推進事業, 日本医療研究開発機構(AMED), Apr, 2020 - Mar, 2022
-
創薬総合支援事業, 日本医療研究開発機構(AMED), Jan, 2017 - Dec, 2019
-
感染症実用化研究事業, 日本医療研究開発機構(AMED), Apr, 2016 - Mar, 2019
-
感染症研究国際展開戦略プログラム(J-GRID), 日本医療研究開発機構(AMED), Oct, 2015 - Mar, 2018